Literature DB >> 7037025

Haemodynamic and myocardial metabolic effects of captopril in chronic heart failure.

K Chatterjee, J L Rouleau, W W Parmley.   

Abstract

In 15 patients with chronic left ventricular failure caused by ischaemic heart disease, cardiac output and right heart pressures were measured before and after the oral angiotensin-converting enzyme inhibitor, captopril, which was administered in increasing doses. In 12 of 15 patients, coronary blood flow, and in 11 patients myocardial oxygen extraction and consumption and lactate extraction were also determined before and after captopril therapy. Cardiac index and stroke volume index increased by an average of 25% and 27%, respectively. Pulmonary capillary wedge pressure also decreased in all patients (average 27%), suggesting improved left ventricular function. The rate-pressure product, coronary blood flow, and myocardial oxygen consumption decreased significantly; in one of 11 patients there was myocardial lactate production, despite decreased myocardial oxygen demand and consumption. These findings suggest that in patients with chronic heart failure, improved left ventricular function with captopril is generally associated with decreased metabolic cost and that deterioration of metabolic function occurs infrequently.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7037025      PMCID: PMC481127          DOI: 10.1136/hrt.47.3.233

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  17 in total

1.  Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man.

Authors:  H Gavras; H R Brunner; G A Turini; G R Kershaw; C P Tifft; S Cuttelod; I Gavras; R A Vukovich; D N McKinstry
Journal:  N Engl J Med       Date:  1978-05-04       Impact factor: 91.245

2.  Thermodilution cardiac output determination with a single flow-directed catheter.

Authors:  J S Forrester; W Ganz; G Diamond; T McHugh; D W Chonette; H J Swan
Journal:  Am Heart J       Date:  1972-03       Impact factor: 4.749

3.  Differential response of large and small coronary arteries to nitroglycerin and angiotensin. Autoregulation and tachyphylaxis.

Authors:  M V Cohen; E S Kirk
Journal:  Circ Res       Date:  1973-10       Impact factor: 17.367

4.  Relationship of plasma volume changes to resistance and capacitance vessel effects of sympathomimetic amines and angiotensin in man.

Authors:  J N Cohn
Journal:  Clin Sci       Date:  1966-04       Impact factor: 6.124

5.  Measurement of coronary sinus blood flow by continuous thermodilution in man.

Authors:  W Ganz; K Tamura; H S Marcus; R Donoso; S Yoshida; H J Swan
Journal:  Circulation       Date:  1971-08       Impact factor: 29.690

6.  Myocardial hypoxia and anerobic metabolism in coronary heart disease.

Authors:  W A Neill
Journal:  Am J Cardiol       Date:  1968-10       Impact factor: 2.778

7.  Coronary sinus reflux. A source of error in the measurement of thermodilution coronary sinus flow.

Authors:  D G Mathey; K Chatterjee; J V Tyberg; J Lekven; B Brundage; W W Parmley
Journal:  Circulation       Date:  1978-04       Impact factor: 29.690

8.  Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme.

Authors:  R Davis; H S Ribner; E Keung; E H Sonnenblick; T H LeJemtel
Journal:  N Engl J Med       Date:  1979-07-19       Impact factor: 91.245

9.  Myocardial lactate extraction: multi-determined metabolic function.

Authors:  E W Gertz; J A Wisneski; R Neese; A Houser; R Korte; J D Bristow
Journal:  Circulation       Date:  1980-02       Impact factor: 29.690

10.  Improvement of chronic congestive heart-failure by oral captopril.

Authors:  G A Turini; H R Brunner; M Gribic; B Waeber; H Gavras
Journal:  Lancet       Date:  1979-06-09       Impact factor: 79.321

View more
  17 in total

Review 1.  Cardiac effects of angiotensin converting enzyme inhibitors.

Authors:  N Sharpe
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 2.  Inhibitors of the renin-angiotensin system in established cardiac failure.

Authors:  K Chatterjee
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

3.  Angiotensin-converting-enzyme inhibitors in hemodynamic congestion: a meta-analysis of early studies.

Authors:  Alexander Jobs; Amr Abdin; Suzanne de Waha-Thiele; Ingo Eitel; Holger Thiele; Cor de Wit; Reinhard Vonthein
Journal:  Clin Res Cardiol       Date:  2019-03-20       Impact factor: 5.460

4.  The effects of felodipine in angina pectoris.

Authors:  A R Lorimer; P MacFarlane; S Pringle; M P Barbour; Y Fox; T D Lawrie
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 5.  Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  E Saltiel; A G Ellrodt; J P Monk; M S Langley
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

Review 6.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 7.  Vasodilators.

Authors:  T T Zsotér
Journal:  Can Med Assoc J       Date:  1983-09-01       Impact factor: 8.262

8.  Sustained haemodynamic and clinical effects of captopril in long-term treatment of severe chronic congestive heart failure.

Authors:  S Ricci; P Zaniol; V Teglio; P Baraldi; G Mattioli
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

9.  Increased coronary sinus lactate concentration during pacing induced angina pectoris after clinical improvement by glyceryl trinitrate.

Authors:  J P Bagger; T T Nielsen; P Henningsen
Journal:  Br Heart J       Date:  1983-11

Review 10.  Angiotensin converting enzyme inhibitors versus digoxin for the treatment of congestive heart failure.

Authors:  I Crozier; H Ikram
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.